About: Immutep

An Entity of Type: Public company, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.

Property Value
dbo:abstract
  • Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: Eftilagimod alpha, (lab name: IMP321) which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis (en)
dbo:foundingYear
  • 2001-01-01 (xsd:gYear)
dbo:industry
dbo:keyPerson
dbo:location
dbo:product
dbo:thumbnail
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 46505228 (xsd:integer)
dbo:wikiPageLength
  • 15361 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1085167624 (xsd:integer)
dbo:wikiPageWikiLink
dbp:foundation
  • 2001 (xsd:integer)
dbp:industry
dbp:keyPeople
dbp:location
dbp:logo
  • Logo-immutep-lag-3.svg (en)
dbp:name
  • Immutep Ltd (en)
dbp:products
  • IMP321, GSK2831781, CVac LAG-3 Immunotherapy (en)
dbp:tradedAs
  • NASDAQ:IMMP (en)
dbp:type
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. (en)
rdfs:label
  • Immutep (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
foaf:name
  • Immutep Ltd (en)
is dbo:institution of
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License